| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Company Name: |
InvivoChem |
| Tel: |
+1-708-310-1919 +1-13798911105 |
| Email: |
sales@invivochem.cn |
|
| | ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Basic information |
| | ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 250 mg/mL (421.81 mM) | | form | Solid | | pka | 10.471±0.10(predicted) | | color | Light yellow to yellow |
| | ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Usage And Synthesis |
| Biological Activity | Targapremir-210 (TGP-210) is a potent and selective miR-210 inhibitor. It can inhibits pre-miR-210 processing with high affinity (Kd~200 nM). | | in vitro | Targapremir-210 decreases mature miR-210 levels in MDA-MB-231 cells cultured under hypoxic conditions, with an IC 50 of～200 nM.
It (200 nM) induces apoptosis in MDA-MB-231 cells is selective for the hypoxic environment. Targapremir-210 induces apoptosis in cells under hypoxic conditions and does not induce apoptosis in MDA-MB-231 cells cultured in normoxia. | | in vivo | Targapremir-210 (100 μL of 200 nM; single ip injection) impedes MDA-MB-231 triple negative breast cancer (TNBC) cells proliferation in vivo. It is able to reach the tumor and sustain for the entire 21-day period, and decreases tumor burden in a TNBC mouse model. | | target | IC50: 200 nM (miR-210, in MDA-MB-231 cells). | | storage | Store at -20°C |
| | ButanaMide, N-(3-azidopropyl)-4-[3-[6-(4-Methyl-1-piperazinyl)[2,6'-bi-1H-benziMidazol]-2'-yl]phenoxy]- Preparation Products And Raw materials |
|